Merck osteoporosis drug shows clear benefits, trial halted

July 11 (Reuters) - A pivotal trial of Merck & Co's experimental osteoporosis drug Odanacatib has shown that it reduces fracture risk, prompting outside monitors to recommend that the study be st…
Read the full story: Reuters: Healthcare